SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

🎯 Drug Targets

Browse 8 drug targets with druggability analysis, composite scores, and clinical context

8
Targets
0
High Druggability
0.54
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 2Low: 6Unknown: 0
Avg druggability score: 0.419
Clinical Pipeline
Approved: 2Phase III: 1Phase II: 2Phase I: 3Preclinical: 0
Total compounds: 14 · Approved: 2
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Receptor (11) Transcription Factor (11) Ligand (10) Epigenetic Regulator (8) Transporter (8) Kinase (7) Other (4) Protease (4) Chaperone (4)
Druggability Low (97) Medium (56) Undruggable (19) High (10) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=epigenetic_regulator — 8 results
SIRT6 Sirtuin-6 Phase I
Epigenetic Regulator Low Druggability
Score
0.59
Drug.
0.41
Safety
0.60
Drugs
1
Hyps
2
Papers
36
Small molecule activation or inhibition of NAD+-dependent deacetylase activity
TET2 Tet methylcytosine dioxygenase 2 Phase II
Epigenetic Regulator Low Druggability
Score
0.58
Drug.
0.42
Safety
0.60
Drugs
2
Hyps
6
Papers
65
Small molecule enhancers of TET2 enzymatic activity or cofactor supplementation
PRMT1 Protein arginine methyltransferase 1 Phase I
Epigenetic Regulator Low Druggability
Score
0.57
Drug.
0.36
Safety
0.50
Drugs
1
Hyps
1
Papers
32
Small molecule inhibitor of protein arginine methyltransferase activity
DNMT1 DNA methyltransferase 1 Approved
Epigenetic Regulator Medium Druggability
Score
0.57
Drug.
0.52
Safety
0.30
Drugs
2
Hyps
6
Papers
36
Small molecule inhibitor of DNA methyltransferase activity
HDAC3 Histone Deacetylase 3 Approved
Epigenetic Regulator Low Druggability
Score
0.56
Drug.
0.41
Safety
0.40
Drugs
2
Hyps
5
Papers
36
Small molecule inhibitor of histone deacetylase enzymatic activity
KDM6A Lysine demethylase 6A Phase I
Epigenetic Regulator Low Druggability
Score
0.52
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
1
Papers
36
Small molecule inhibition of histone demethylase activity
SIRT1 NAD-dependent protein deacetylase sirtuin-1 Phase III
Epigenetic Regulator Medium Druggability
Score
0.46
Drug.
0.48
Safety
0.73
Drugs
3
Hyps
2
Papers
44
SIRT1 activation via NAD+ precursors or allosteric activators deacetylates tau (reducing aggregation), enhances mitophagy, and restores circadian gene expression
BRD4 Bromodomain-containing protein 4 Phase II
Epigenetic Regulator Low Druggability
Score
0.45
Drug.
0.40
Safety
0.62
Drugs
2
Hyps
1
Papers
35
BRD4 inhibition reduces neuroinflammatory super-enhancer activity while biased BRD4 modulators can selectively restore neuroprotective gene expression
Exchange | Dashboard